На этой странице перечислены больницы направления «Хирургическая гастроэнтерология» (включая Hepatitis B Treatment) в Мумбаи, Индия, включая Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai и другие.
Спросите нас о «Hepatitis B Treatment» в Мумбаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 17 аккредитованных больниц (Хирургическая гастроэнтерология) в Мумбаи, Индия
Рекомендуем🇮🇳 Nanavati Super Specialty Hospital
Больница занимает 1-е место в этом списке по указанному рейтингу (5/5, 12 отзывов).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.8/5, 1800 отзывов).
🇮🇳 Tata Memorial Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.8/5, 2500 отзывов).
🇮🇳 Apollo Hospitals, Navi Mumbai
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 512 отзывов).
🇮🇳 Gleneagles Hospital, Mumbai
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 615 отзывов).
🇮🇳 Lilavati Hospital And Research Centre
Больница занимает 6-е место в этом списке по указанному рейтингу (4.8/5, 724 отзывов).
🇮🇳 Jaslok Hospital
Больница занимает 7-е место в этом списке по указанному рейтингу (4.6/5, 129 отзывов).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.6/5, 183 отзывов).
🇮🇳 Medicover Hospital, Navi Mumbai
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 143 отзывов).
🇮🇳 KIMS Hospitals, Thane
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 58 отзывов).
🇮🇳 Fortis Hospital, Mulund
Больница занимает 11-е место в этом списке по указанному рейтингу (4.5/5, 79 отзывов).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Больница занимает 12-е место в этом списке по указанному рейтингу (4.5/5, 83 отзывов).
🇮🇳 Wockhardt Hospital
Больница занимает 13-е место в этом списке по указанному рейтингу (4.4/5, 30 отзывов).
🇮🇳 Wockhardt Super Speciality Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.4/5, 48 отзывов).
🇮🇳 S. L. Raheja Hospital
Больница занимает 15-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Saifee Hospital
Больница занимает 16-е место в этом списке по указанному рейтингу (4.3/5, 97 отзывов).
🇮🇳 Dr. L H Hiranandani Hospital
Больница занимает 17-е место в этом списке по указанному рейтингу (4.3/5, 141 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Хирургическая гастроэнтерология» указано среди её специализаций и она находится в Мумбаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «hepatitis b treatment» в Мумбаи, Индия?
Выбор подходящей больницы для «hepatitis b treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Хирургическая гастроэнтерология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Hepatitis B Treatment»
Hepatitis B treatment encompasses a spectrum of antiviral therapies, immunomodulatory protocols, and — in advanced cases — liver transplantation, with modern regimens achieving sustained viral suppression (HBsAg loss) in up to 90% of appropriately selected patients. International patients increasingly travel to India and the UAE for this treatment, drawn by world-class hepatology centres, significantly lower costs compared to Western markets, and seamless access to cutting-edge diagnostics such as FibroScan elastography and quantitative HBsAg assays. GAF Healthcare connects patients to JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed facilities in Dubai and Abu Dhabi, providing end-to-end medical travel coordination. Hospital Stay: 3–7 days (for initial antiviral induction workup or acute/decompensated cases requiring inpatient stabilisation; outpatient antiviral programmes require no hospitalisation) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (for medically stable patients on oral antiviral therapy; liver transplant recipients require 6–8 weeks minimum before air travel is cleared) • Success Rate: 85–90% (sustained virological response / HBsAg loss with modern NUC therapy; up to 95% for liver transplantation 5-year patient survival in high-volume centres)
Clinical Overview
Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus (HBV), a partially double-stranded DNA virus of the Hepadnaviridae family. Infection triggers a complex immune-mediated inflammatory cascade within hepatocytes, leading to progressive necroinflammation, fibrosis, and — if untreated — cirrhosis and hepatocellular carcinoma (HCC). The virus integrates covalently closed circular DNA (cccDNA) into the host hepatocyte nucleus, forming a transcriptional template that persists even during antiviral therapy, which is the principal reason HBV is considered a chronic, manageable condition rather than a routinely curable one with current standard-of-care agents. The natural history of chronic HBV is characterised by distinct immunological phases: the HBeAg-positive immune-tolerant phase, the HBeAg-positive immune-active phase, the HBeAg-negative immune-active phase, and the HBsAg-negative 'occult' phase. Clinical decision-making — including the determination of when to initiate therapy — is guided by serum HBV DNA quantification (IU/mL), ALT levels relative to the upper limit of normal (ULN), liver biopsy or non-invasive fibrosis assessment (METAVIR scoring, FibroScan kPa values, FIB-4 index), and HBsAg quantification (qHBsAg). Patients with HBV DNA >2,000 IU/mL, elevated ALT, or evidence of fibrosis ≥F2 on elastography are generally considered treatment candidates under EASL, AASLD, and APASL guidelines. The current standard of care for chronic HBV involves nucleos(t)ide analogues (NUCs) — specifically tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), or entecavir (ETV) — as first-line therapy due to their high potency, high barrier to resistance, and favourable safety profiles. Pegylated interferon alfa-2a (PEG-IFN-α2a) remains an alternative finite-duration therapy (48 weeks) for a subset of patients, particularly younger HBeAg-positive individuals with high ALT and low HBV DNA, with the goal of achieving HBeAg seroconversion and ideally HBsAg loss. Emerging investigational agents — including capsid assembly modulators (CAMs), RNA interference (RNAi) therapeutics such as siRNA and antisense oligonucleotides (ASOs) targeting cccDNA transcription, and novel immune modulators — are in late-phase clinical trials and available through academic centres in both India and the UAE.
Who is a Candidate?
• Patients with confirmed chronic HBV infection (HBsAg-positive for >6 months) • HBeAg-positive or HBeAg-negative chronic hepatitis B with HBV DNA >2,000 IU/mL AND ALT >1× ULN • Patients with HBV DNA >20,000 IU/mL regardless of ALT if liver biopsy or FibroScan confirms ≥F2 fibrosis or necroinflammatory activity ≥A2 • Patients with compensated or decompensated cirrhosis secondary to HBV (any detectable HBV DNA level warrants treatment) • HBV-related hepatocellular carcinoma (HCC) requiring antiviral suppression alongside oncological treatment (TACE, SBRT, sorafenib/lenvatinib) • Patients with HBV reactivation in the context of immunosuppressive therapy (chemotherapy, biologics, corticosteroids) • Liver transplant candidates with HBV-related end-stage liver disease • Co-infected patients (HBV/HIV, HBV/HDV) requiring specialised combination regimens Required Diagnostic Workup Before Treatment Initiation: • HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc (IgM and IgG) serology panel • Quantitative HBV DNA (PCR, IU/mL) — baseline viral load • Quantitative HBsAg (qHBsAg, IU/mL) — predictive of treatment response • Liver function tests (ALT, AST, GGT, ALP, bilirubin, albumin, PT/INR) • Complete blood count, renal function panel (eGFR — critical before TDF selection) • FibroScan transient elastography (LSM in kPa) and/or FIB-4 index calculation • Liver biopsy (METAVIR scoring) if non-invasive tests are inconclusive • Abdominal ultrasound with Doppler (hepatosplenomegaly, portal hypertension assessment) • AFP (alpha-fetoprotein) for HCC surveillance • Hepatitis C (anti-HCV), HIV, and HDV (anti-HDV) co-infection screening • MELD score calculation for cirrhotic/transplant candidates Contraindications / Special Cautions: • PEG-IFN is contraindicated in decompensated cirrhosis, autoimmune hepatitis, severe psychiatric illness, pregnancy, and uncontrolled thyroid disease • TDF requires dose adjustment in patients with eGFR <50 mL/min; TAF is preferred in renal impairment • Liver transplantation is contraindicated in active extrahepatic malignancy, uncontrolled systemic infection, severe cardiopulmonary disease, or ongoing substance abuse
Treatment Options & Approaches
ANTIVIRAL PHARMACOTHERAPY (First-Line, Non-Surgical) Nucleos(t)ide Analogues (NUCs): • Tenofovir Alafenamide (TAF, 25 mg/day): The current preferred first-line agent for most patients. TAF delivers tenofovir to hepatocytes via hepatic first-pass metabolism at 1/10th the plasma concentration of TDF, resulting in superior renal and bone safety profiles with equivalent antiviral potency. Resistance rate: <1% at 3 years. • Tenofovir Disoproxil Fumarate (TDF, 300 mg/day): Highly effective, low-cost generic option widely used in India and the UAE. Preferred in pregnancy. Monitor eGFR and bone mineral density during long-term use. • Entecavir (ETV, 0.5 mg/day; 1 mg/day in lamivudine-experienced patients): High barrier to resistance. Preferred in patients with renal insufficiency relative to TDF. • Lamivudine and Adefovir are now largely obsolete as monotherapy due to high resistance rates and should not be used as first-line agents. Pegylated Interferon Alfa-2a (PEG-IFN-α2a): • 180 mcg subcutaneous injection weekly for 48 weeks. • Achieves HBeAg seroconversion in ~30% and HBsAg loss (functional cure) in 3–7% of HBeAg-positive patients at week 48, rising to 11% at 5-year follow-up. • Optimal candidates: Young age, high ALT (>5× ULN), low HBV DNA (<2×10^8 IU/mL), HBV genotype A or B, qHBsAg <20,000 IU/mL at baseline (the TREAT-B stopping rule). • Side effects require active monitoring: flu-like syndrome, cytopenias, neuropsychiatric effects, thyroid dysfunction. Combination and Sequential Strategies: • PEG-IFN + NUC add-on or switch strategies are used in select patients to enhance HBsAg loss rates (ARES, OSST, New Switch trials protocols). • HBV/HDV co-infected patients: Bulevirtide (Hepcludex) — an entry inhibitor — is the first approved therapy for chronic HDV infection and is available in specialist centres. ADVANCED & INVESTIGATIONAL THERAPIES (Available at Tertiary Centres in India and UAE): • Capsid Assembly Modulators (CAMs): JNJ-56136379 (Morphothiadin) and others in Phase 3 trials — disrupt HBV pregenomic RNA encapsidation and cccDNA production. • RNA Interference (RNAi) Agents: Vir-2218, JNJ-3989 (siRNA) and GSK3228836 (ASO) reduce HBsAg levels by >90% and are being evaluated in combination with NUCs for functional cure. • Immune Modulators: Therapeutic HBV vaccines, TLR7/8 agonists, PD-1/PD-L1 checkpoint inhibitors being trialled to restore HBV-specific T-cell immunity. • Clinical trial access is available through AIIMS New Delhi, Tata Memorial Centre Mumbai, and Cleveland Clinic Abu Dhabi for eligible patients. SURGICAL AND INTERVENTIONAL OPTIONS: Liver Transplantation (Orthotopic Liver Transplantation — OLT): • Indicated for HBV-related decompensated cirrhosis (Child-Pugh B/C, MELD score ≥15) or early-stage HCC within Milan criteria (single lesion ≤5 cm or up to 3 lesions ≤3 cm, no vascular invasion, no extrahepatic spread). • Technique: Standard orthotopic transplantation with piggyback hepatic vein anastomosis or caval replacement. Living donor liver transplantation (LDLT) is a major strength of Indian centres (right lobe LDLT, volume-measured graft-to-recipient weight ratio >0.8%). • Post-transplant HBV prophylaxis: Hepatitis B immunoglobulin (HBIG) in combination with NUC therapy (typically TDF or ETV) to prevent HBV recurrence — recurrence rates <5% with modern protocols. • 5-year patient survival post-OLT: 80–90% in high-volume centres. HCC-Directed Interventional Procedures (for HBV-related liver cancer): • Transarterial Chemoembolisation (TACE): For intermediate-stage HCC (BCLC-B); drug-eluting bead TACE (DEB-TACE) offers reduced systemic toxicity vs conventional TACE. • Transarterial Radioembolisation (TARE / SIRT): Yttrium-90 microsphere therapy for HCC with or without portal vein involvement. • Stereotactic Body Radiotherapy (SBRT): Increasingly used as bridge-to-transplant or definitive therapy for HCC ≤5 cm. • Radiofrequency Ablation (RFA) / Microwave Ablation (MWA): For early-stage HCC (BCLC-A) ≤3 cm; laparoscopic or percutaneous ultrasound/CT-guided. • Systemic oncological therapy: Atezolizumab + Bevacizumab (IMbrave150 regimen) as first-line for advanced HCC; sorafenib and lenvatinib as alternative first-line; cabozantinib, regorafenib as second-line.
Восстановление
PHASE 1 — PRE-TRAVEL PREPARATION (2–4 weeks before departure) • Share all existing medical records with GAF Healthcare: prior HBV serology, HBV DNA PCR results, liver imaging, biopsy reports, and current medications. • GAF Healthcare's medical team reviews records and matches patient with the appropriate specialist (hepatologist, transplant surgeon, or interventional oncologist). • Preliminary treatment plan and cost estimate issued within 48–72 hours. • E-Medical visa application support initiated for India (Indian e-Medical Visa — typically granted within 3–5 business days); visa-on-arrival or prior visa-free entry facilitated for UAE. • Travel insurance with medical coverage confirmation advised. PHASE 2 — ARRIVAL & DIAGNOSTIC WORKUP (Days 1–3 in country) • GAF Healthcare representative meets patient at airport with wheelchair assistance if required; transfer to partner hospital or serviced accommodation. • Comprehensive hepatology workup conducted: quantitative HBV DNA, qHBsAg, complete liver function panel, FibroScan elastography (result available same day), abdominal ultrasound with Doppler, AFP. • Specialist consultation (Day 1–2): Hepatologist reviews all investigations and confirms diagnosis, disease stage (METAVIR fibrosis, Child-Pugh, MELD scores for cirrhotic patients), and individualised treatment plan. • Multidisciplinary team (MDT) review if HCC or transplant workup required — includes hepatology, transplant surgery, interventional radiology, oncology. PHASE 3A — ANTIVIRAL TREATMENT INITIATION (Outpatient, Days 3–7) • For patients managed with NUC monotherapy (the majority): Medication prescribed and dispensed; patient educated on adherence, monitoring parameters, and potential side effects. • Baseline renal function and bone density tests completed before TDF initiation. • For PEG-IFN candidates: First injection administered under supervision with 30-minute observation; self-injection training provided. • Follow-up appointment scheduled at week 4 (HBV DNA, ALT, CBC) — can be conducted remotely via GAF Healthcare's telemedicine platform. PHASE 3B — LIVER TRANSPLANTATION (Inpatient, for surgical candidates) • Pre-operative assessment: Cardiopulmonary evaluation (echocardiography, right heart catheterisation if indicated), anaesthesia fitness, cross-sectional imaging (triphasic CT liver volumetry or MRI), MELD recalculation. • Living donor evaluation (for LDLT): CT volumetry, MRI biliary anatomy, cardiac and psychological clearance of donor. • Surgery: OLT procedure duration 6–12 hours; conducted under general anaesthesia. ICU admission post-operatively (Days 1–5). Extubation target: 12–24 hours. • Hospital ward stay: Days 5–14 post-surgery (uncomplicated cases). • Post-transplant protocol: HBIG IV infusion (Day 0 and daily for 7 days), followed by long-term NUC + low-dose HBIG or NUC monotherapy with HBsAg monitoring. • Rejection surveillance: Tacrolimus trough levels monitored daily initially; target 8–12 ng/mL in first month. PHASE 4 — POST-TREATMENT RECOVERY & DISCHARGE PLANNING • For antiviral therapy patients: Clinically stable patients may typically return home within 1–2 weeks after confirming treatment tolerability; follow-up HBV DNA at week 4 via telemedicine. • For liver transplant recipients: Minimum 6-week in-country stay required post-surgery. Week 4–6 milestones: ambulation without assistance, oral immunosuppression optimised, first biopsy-proven rejection episode (if any) treated. Clearance for international flight only after hepatologist and transplant surgeon written sign-off. • GAF Healthcare provides detailed discharge summary, all histopathology and radiology reports in English (and local language if required), medication reconciliation list, and first follow-up telemedicine appointment scheduling. • Long-term follow-up: HBV DNA and ALT monitoring every 3–6 months indefinitely; HCC surveillance ultrasound + AFP every 6 months for cirrhotic patients and transplant recipients.
Возможные риски
As with all medical therapies, Hepatitis B treatment carries procedure- and drug-specific risks that patients must understand before initiating care. Nucleos(t)ide Analogues (NUCs): Generally well-tolerated with a favourable long-term safety profile. TDF carries a risk of proximal renal tubular dysfunction (Fanconi syndrome) and reduced bone mineral density with prolonged use — annual eGFR and DEXA monitoring is recommended. TAF significantly mitigates these risks. Entecavir carries a theoretical risk of lactic acidosis in patients with decompensated liver disease and should be used with caution in that setting. Abrupt discontinuation of any NUC can trigger severe acute-on-chronic hepatitis flares with rapid HBV DNA rebound and hepatic decompensation — therapy must never be stopped without physician supervision. Pegylated Interferon (PEG-IFN): Significant side-effect burden including influenza-like syndrome (>70%), fatigue, cytopenias (neutropaenia requiring G-CSF in some cases), depression and suicidal ideation (requires psychiatric pre-screening), autoimmune thyroiditis (8–10%), retinopathy, and alopecia. Requires weekly haematological and biochemical monitoring. HBV Reactivation Risk: Patients receiving immunosuppressive therapies (anti-CD20 agents such as rituximab, corticosteroids, TNF-alpha inhibitors) are at high risk of HBV reactivation. Pre-emptive antiviral prophylaxis with entecavir or TDF is mandatory in HBsAg-positive individuals; HBsAg-negative, anti-HBc-positive patients also require monitoring or prophylaxis depending on the immunosuppressive regimen. Liver Transplantation Risks: Major surgical risks include primary non-function of the graft (<5%), hepatic artery thrombosis (2–5%, higher in paediatric cases), biliary complications (anastomotic stricture, bile leak — 10–15%), acute cellular rejection (20–40% in first year, most episodes treatable), chronic rejection (<5%), post-transplant de novo malignancy, and opportunistic infections related to immunosuppression (CMV, Pneumocystis jirovecii, Aspergillus). Calcineurin inhibitor toxicity (nephrotoxicity, hypertension, neurotoxicity) requires lifelong drug-level monitoring. HBV recurrence post-transplant is low (<5%) with modern prophylaxis but remains a permanent concern requiring lifelong antiviral therapy. HCC-Related Interventions: TACE is associated with post-embolisation syndrome (fever, abdominal pain, nausea — managed supportively), hepatic abscess (<1%), and non-target embolisation. Ablative therapies carry risks of bleeding, bile duct injury, and tumour seeding (rare, <0.5%). All risks are discussed transparently by GAF Healthcare's partner physicians before written informed consent is obtained.
Почему GAF Healthcare
GAF Healthcare provides a fully integrated, end-to-end medical travel service that addresses every logistical need from initial inquiry to safe repatriation. VISA & ENTRY SUPPORT: • India: GAF Healthcare coordinates the Indian e-Medical Visa application on behalf of the patient and one accompanying attendant. The e-Medical Visa (e-MV) supports up to 3 entries within 60 days and is typically processed within 3–5 business days. Patients from over 150 countries are eligible. GAF Healthcare provides the mandatory official hospital invitation letter required for the application. • UAE (Dubai / Abu Dhabi): Citizens of over 50 countries (including the EU, US, UK, and most GCC nationals) receive a visa-on-arrival or enjoy visa-free access for 30–90 days. Patients from other nationalities are assisted with medical visit visa applications through UAE-based PRO services partnered with GAF Healthcare. Both Dubai Health Authority (DHA) and Department of Health Abu Dhabi (DoH) facilities are accessible under standard tourist or visit visa categories. AIRPORT & GROUND TRANSFERS: • Dedicated private vehicle transfers (wheelchair-accessible where required) from the airport to the hospital and accommodation are arranged for the patient and attendant. GAF Healthcare's local coordinators are present at arrival to assist with luggage and check-in. MEDICAL TRANSLATION & INTERPRETATION: • Professional medical interpreters are available for Arabic, Russian, Kazakh, French, Swahili, Bangla, and other languages. All medical reports, discharge summaries, and consent forms are translated into the patient's preferred language at no additional cost for GAF Healthcare-coordinated cases. ACCOMMODATION: • Partnered serviced apartments and hotel rooms within 1–3 km of the treating hospital are arranged for the patient's attendant. Options range from budget-friendly to premium suites. Accommodation for extended stays (transplant programmes, 6–8 week stays) is negotiated at preferential rates through GAF Healthcare. REMOTE MONITORING & TELEMEDICINE: • Post-discharge follow-up is managed through GAF Healthcare's telemedicine platform, connecting patients with their treating hepatologist for HBV DNA result reviews, medication adjustments, and clinical queries — regardless of where the patient is located after returning home. FINANCIAL TRANSPARENCY: • All-inclusive cost estimates are provided upfront in writing. No hidden billing. Direct hospital billing is arranged; GAF Healthcare does not add service surcharges to the hospital invoice.
Частые вопросы о процедуре «Hepatitis B Treatment»
What is the cost of Hepatitis B treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after Hepatitis B treatment?
What is the success rate of Hepatitis B treatment?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «hepatitis b treatment» в Мумбаи, Индия
Найдите лучшие больницы для «hepatitis b treatment» в Мумбаи, Индия
На этой странице представлено 17 больниц в Мумбаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Hepatitis B Treatment» в Мумбаи, Индия
Сколько больниц направления «Хирургическая гастроэнтерология» представлено в Мумбаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Мумбаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Hepatitis B Treatment» в Мумбаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.